Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B)

Acta Ophthalmologica

Volumn 96, Issue 1, 2018, Pages e10-e18

  Hattenbach, Lars Olof ^a   Feltgen, Nicolas ^b   Bertelmann, Thomas ^b,c   Schmitz Valckenberg, Steffen ^d   Berk, Hüsnü ^e   Eter, Nicole ^f   Lang, Gabriele E ^g   Rehak, Matus ^h,i   Taylor, Simon R ^j   Wolf, Armin ^k   Weiss, Claudia ^c   Paulus, Eva Maria ^c   Pielen, Amelie ^l   Hoerauf, Hans ^b  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c Novartis Pharma GmbH   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e St Elisabeth Hospital   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g UNIVERSITY OF ULM   (Germany)

^h UNIVERSITY OF LEIPZIG   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY OF SURREY   (United Kingdom)

^k UNIVERSITY OF MUNICH   (Germany)

^l HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

branch retinal vein occlusion; dexamethasone; PRN; ranibizumab

Indexed keywords

DEXAMETHASONE; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; VASCULOTROPIN A;

ADULT; ARTICLE; BEST CORRECTED VISUAL ACUITY; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CELLULITIS; CONJUNCTIVITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INJECTION SITE REACTION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; RETINA FOVEA; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; TIME FACTOR; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FOVEA CENTRALIS; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RANIBIZUMAB; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85014110362     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.13381     Document Type: Article

References (33)

1. Abdolrahimzadeh S, Plateroti P, Scarinci F & Plateroti AM (2016): Accidental intralenticular dexamethasone intravitreal implant with the resolution of macular oedema in central retinal vein occlusion. Acta Ophthalmol 94: e810–e811.
2. Aref AA, Scott IU, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC & SSI Group (2015): Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE study report 15. JAMA Ophthalmol 133: 1022–1029.
3. Bertelmann T, Kicova N, Mennel S, Schmidt J, Irle S, Sekundo W & Schulze S (2016): The impact of posterior vitreous adhesion on ischaemia in eyes with retinal vein occlusion. Acta Ophthalmol 94: e43–e48.
4. Bertelsen M, Linneberg A, Rosenberg T, Christoffersen N, Vorum H, Gade E & Larsen M (2012): Comorbidity in patients with branch retinal vein occlusion: case-control study. BMJ 345: e7885.
5. Bezatis A, Spital G, Höhn F et al. (2013): Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up – the SOLO study. Acta Ophthalmol 91: e340–e347.
6. BRVO Study Group (1984): Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98: 271–282.
7. Campochiaro PA, Heier JS, Feiner L et al. (2010): Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117: 1102–1112.e1101.
8. Campochiaro PA, Sophie R, Pearlman J et al. (2014): Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121: 209–219.
9. COMRADE-Extension. Available at: https://clinicaltrials.gov/ct2/show/NCT01580020. (Accessed Sep 2014).
10. EMA/SmPC (2013): European Medicines Agency. Summary of product characteristics. Lucentis 10 mg/ml solution for injection.
11. EMA/SmPC (2015): European Medicines Agency. Summary of product characteristics. Ozurdex 700 micrograms intravitreal implant in applicator.
12. Ferrara N, Damico L, Shams N, Lowman H & Kim R (2006): Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26: 859–870.
13. Gado AS & Macky TA (2014): Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison. Clin Exp Ophthalmol 42: 650–655.
14. Giudice GL, Eandi CM, Foltran F, Tavolato M, Maritan V, Babighian S & Galan A (2012): Short-term effects of dexamethasone intravitreal implant for retinal macular edema. A consecutive small case series. Invest Ophthalmol Vis Sci 53: 508.
15. Grzybowski A (2015): Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome. Am J Ophthalmol 160: 842–843.
16. Guignier B, Subilia-Guignier A, Fournier I, Ballonzoli L, Speeg-Schatz C & Gaucher D (2013): Prospective pilot study: efficacy of intravitreal dexamethasone and bevacizumab injections in the treatment of macular oedema associated with branch retinal vein occlusion. Ophthalmologica 230: 43–49.
17. Haller JA, Bandello F, Belfort R et al. (2010): Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117: 1134–1146.
18. Haller JA, Bandello F, Belfort R et al. (2011): Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118: 2453–2460.
19. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG & Lai P (2012): Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119: 802–809.
20. Higham A, Jacob S, Cox M, Baker C, Al-Husainy S, Sivaraj R & Gibson JM (2016): The efficacy and safety of intravitreal dexamethasone implants for macular oedema secondary to retinal vein occlusion: 3-year experience. Acta Ophthalmol 94: e674–e675.
21. Kim YJ, Sung KR, Lee KS, Joe SG, Lee JY, Kim JG & Yoon YH (2014): Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure. Am J Ophthalmol 157: 1266–1271.e1261.
22. Kim M, Lee DH, Byeon SH, Koh HJ, Kim SS & Lee SC (2015): Comparison of intravitreal bevacizumab and dexamethasone implant for the treatment of macula oedema associated with branch retinal vein occlusion. Br J Ophthalmol 99: 1271–1276.
23. Maturi RK, Chen V, Raghinaru D, Bleau L & Stewart MW (2014): A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusion. Clinical Ophthalmol 8: 1057–1064.
24. Mayer WJ, Wolf A, Kernt M, Kook D, Kampik A, Ulbig M & Haritoglou C (2013): Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye (Lond) 27: 816–822.
25. Ng WY, Tan GS, Ong PG et al. (2015): Incidence of myocardial infarction, stroke, and death in patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol 159: 557–564.e551.
26. Pielen A, Feltgen N, Isserstedt C, Callizo J, Junker B & Schmucker C (2013): Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS One 8: e78538.
27. Pielen A, Mirshahi A, Feltgen N et al. (2015): Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol 93: e29–e37.
28. ®) for retinal vein occlusion. Ophthalmologica 229: 21–25.
29. Rezar-Dreindl S, Eibenberger K, Pollreisz A et al. (2016): Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion. Acta Ophthalmol [Epub ahead of print].
30. Shah AM, Bressler NM & Jampol LM (2011): Does laser still have a role in the management of retinal vascular and neovascular diseases? Am J Ophthalmol 152: 332–339.e331.
31. Sivaprasad S, Amoaku WM, Hykin P & RG Group (2015): The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary. Eye (Lond) 29: 1640.
32. Szurman GB, Januschowski K, Szurman P et al. (2016): Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicentre study. Acta Ophthalmol [Epub ahead of print].
33. Tan MH, McAllister IL, Gillies ME, Verma N, Banerjee G, Smithies LA, Wong WL & Wong TY (2014): Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion. Am J Ophthalmol 157: 237–247.e231.